Business Context and Reporting Period
This Form 8-K was filed by Microbot Medical Inc. on April 13, 2026. The filing reports on the successful execution of the limited market release of the company's LIBERTY Endovascular Robotic System and the planned commencement of its full U.S. market release.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on operational milestones rather than financial performance data.
Material Changes and Operational Updates
- Product Launch: The company successfully executed a limited market release of the LIBERTY system and announced the start of the full U.S. market release at the Society of Interventional Radiology (SIR) Annual Scientific Meeting in Toronto (April 11-15, 2026).
- Commercial Adoption: LIBERTY has been adopted by multiple healthcare systems, including Emory Healthcare and Tampa General Hospital, with dozens of hospitals in their networks.
- Procedural Use: The system is being used commercially for Prostate Artery Embolization (PAE), Uterine Fibroid Embolization (UFE), Genicular Artery Embolization (GAE), Y90 mapping/deliveries, and peripheral arterial interventions.
- Sales Expansion: The sales footprint has expanded from four to eight territories. The company aims to reach 12 territories across the U.S. by the end of 2026.
Guidance, Outlook, and Risks
Management indicated plans to broaden sales capabilities and achieve 12 U.S. territories by year-end 2026. The filing includes standard forward-looking statements regarding regulatory milestones and future expectations, noting that actual results may differ due to various factors. No specific financial guidance or quantitative outlook was provided in this text.
Investor Verification Checklist
- Verify the specific date and details of the full U.S. market release at the SIR meeting.
- Confirm the number of hospitals and healthcare systems currently utilizing the LIBERTY system.
- Monitor the progress of sales territory expansion toward the 12-territory goal for 2026.
- Review the full press release (Exhibit 99.1) for additional details on commercial adoption rates.